Clinical Trial Update: Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study) [Phase 1, Phase 2]

View source ↗

Summary

Pfizer sponsored a Phase 1/2 landscape trial evaluating sasanlimab in combination with targeted therapies for advanced non-small cell lung cancer; the study was…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Sasanlimab (sasanlimab)

Snippet

Sponsor: Pfizer | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2023-06-22